C
We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first clinical development programme is researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. We want to transform the patient experience in mental health care. Show more Show less
Investor insights
Funding rounds participated in
$150M sweet spot round size
Investor type
Public Company
Basic info
Industry
Mental Health Care
Sectors
Mental Health Care
Date founded
2016
Funding rounds raised
Total raised
$150M
from investors over 1 rounds
C
Compass Pathways raised $150M on February 10, 2025